Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II erlotinib study with FDG/FLT PET for early prediction in advanced NSCLC
2005-005393-73Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by University of Cologne. Primary endpoint: Response to therapy with erlotinib, FLT and FDG standard uptake values. Started Dec 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005393-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005393-73.